We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Loading
No, azithromycin should not be used solely as an immunomodulator for acute chest infections in infants under 1 year.
why:
​Lack of Clinical Benefit: Studies show its anti-inflammatory properties do not improve recovery times or outcomes for acute viral infections (like RSV bronchiolitis).
​Antibiotic Resistance: Using an antibiotic strictly for inflammation drives the development of resistant bacterial strains.
​Safety Risks:
It exposes infants to unnecessary adverse effects, including Infantile Hypertrophic Pyloric Stenosis (IHPS), heart rhythm issues (QTc prolongation), and disruption of the developing gut microbiome.
​Only for Chronic Cases:
The immunomodulatory use of azithromycin is reserved for specific chronic respiratory diseases (like Cystic Fibrosis or severe Bronchopulmonary Dysplasia), not acute infections, and its use in patients under 1 year remains highly restricted and specialized.